ResMed Management
Management criteria checks 4/4
ResMed's CEO is Mick Farrell, appointed in Mar 2013, has a tenure of 11.75 years. total yearly compensation is $14.12M, comprised of 8.3% salary and 91.7% bonuses, including company stock and options. directly owns 0.31% of the company’s shares, worth $108.57M. The average tenure of the management team and the board of directors is 3.8 years and 7.1 years respectively.
Key information
Mick Farrell
Chief executive officer
US$14.1m
Total compensation
| CEO salary percentage | 8.3% |
| CEO tenure | 11.8yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.8yrs |
| Board average tenure | 7.1yrs |
Recent management updates
Recent updates
ResMed: Solid Execution, Pricey Valuation
Nov 25Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Nov 13
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Oct 20ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price
Oct 08Why ResMed's Rally Is Just Getting Started
Sep 18ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors
Sep 13ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10Compound Your Wealth With ResMed
Jul 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | US$14m | US$1m | US$1b |
| Mar 31 2024 | n/a | n/a | US$958m |
| Dec 31 2023 | n/a | n/a | US$890m |
| Sep 30 2023 | n/a | n/a | US$907m |
| Jun 30 2023 | US$14m | US$1m | US$898m |
| Mar 31 2023 | n/a | n/a | US$863m |
| Dec 31 2022 | n/a | n/a | US$809m |
| Sep 30 2022 | n/a | n/a | US$786m |
| Jun 30 2022 | US$12m | US$1m | US$779m |
| Mar 31 2022 | n/a | n/a | US$779m |
| Dec 31 2021 | n/a | n/a | US$522m |
| Sep 30 2021 | n/a | n/a | US$500m |
| Jun 30 2021 | US$10m | US$1m | US$475m |
| Mar 31 2021 | n/a | n/a | US$457m |
| Dec 31 2020 | n/a | n/a | US$699m |
| Sep 30 2020 | n/a | n/a | US$680m |
| Jun 30 2020 | US$10m | US$1m | US$622m |
| Mar 31 2020 | n/a | n/a | US$513m |
| Dec 31 2019 | n/a | n/a | US$455m |
| Sep 30 2019 | n/a | n/a | US$419m |
| Jun 30 2019 | US$10m | US$967k | US$405m |
| Mar 31 2019 | n/a | n/a | US$446m |
| Dec 31 2018 | n/a | n/a | US$450m |
| Sep 30 2018 | n/a | n/a | US$335m |
| Jun 30 2018 | US$9m | US$934k | US$316m |
Compensation vs Market: Mick's total compensation ($USD14.12M) is about average for companies of similar size in the US market ($USD12.88M).
Compensation vs Earnings: Mick's compensation has been consistent with company performance over the past year.
CEO
Mick Farrell (52 yo)
11.8yrs
Tenure
US$14,120,829
Compensation
Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 11.8yrs | US$14.12m | 0.31% $ 108.6m | |
| Founder | no data | US$719.69k | 0.055% $ 19.1m | |
| Chief Financial Officer | 18.9yrs | US$3.23m | 0.064% $ 22.3m | |
| Chief Legal Officer & Secretary | 1.4yrs | US$2.15m | 0.0062% $ 2.2m | |
| Chief Product Officer | 8.6yrs | US$3.60m | 0.015% $ 5.2m | |
| Chief Commercial Officer - SaaS | 2.8yrs | US$3.53m | 0.013% $ 4.6m | |
| Chief Information Officer | less than a year | no data | no data | |
| Chief Compliance Officer | 6.9yrs | no data | no data | |
| Chief Marketing Officer | 1.1yrs | no data | no data | |
| Chief People Officer | 3.8yrs | no data | no data | |
| Special Advisor | less than a year | US$6.67m | 0% $ 0 | |
| Chief Strategy Officer | 10yrs | no data | no data |
3.8yrs
Average Tenure
57yo
Average Age
Experienced Management: RMD's management team is considered experienced (3.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 11.8yrs | US$14.12m | 0.31% $ 108.6m | |
| Founder | 35.5yrs | US$719.69k | 0.055% $ 19.1m | |
| Independent Director | 19.3yrs | US$348.72k | 0.011% $ 4.0m | |
| Lead Independent Director | 19.9yrs | US$381.22k | 0.015% $ 5.4m | |
| Independent Non-Executive Director | 5.6yrs | US$329.97k | 0.0046% $ 1.6m | |
| Independent Director | 6.1yrs | US$329.97k | 0.0060% $ 2.1m | |
| Independent Director | 11.1yrs | US$369.97k | 0.011% $ 4.0m | |
| Independent Director | 7.1yrs | US$334.97k | 0.0058% $ 2.0m | |
| Independent Director | less than a year | no data | no data | |
| Independent Director | 3.1yrs | US$329.97k | 0.0026% $ 912.3k | |
| Independent Director | 3.1yrs | US$329.97k | 0.0020% $ 703.3k |
7.1yrs
Average Tenure
60yo
Average Age
Experienced Board: RMD's board of directors are considered experienced (7.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 01:53 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ResMed Inc. is covered by 56 analysts. 23 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| John Hester | ANZ Equities Pty Limited |
| Russell Wright | APP Securities Pty Ltd. |
| David Rescott | Baird |